EPHB3: A Multi-Functional Protein with Potential as A Drug Target

Target Name: EPHB3

NCBI ID: G2049

EPHB3

EPHB3: A Multi-Functional Protein with Potential as A Drug Target

EPHB3 (EPH-like tyrosine kinase-2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the EPH receptor tyrosine kinase family, which is a family of transmembrane proteins that play a crucial role in the development and maintenance of tissues and organs.

One of the unique features of EPHB3 is its structure. It is a 21-kDa protein that consists of a 110 amino acid long extracellular domain and a 94 amino acid long transmembrane domain. The extracellular domain is responsible for the protein's ability to interact with its ligands, which are EPH receptors. The transmembrane domain is responsible for the protein's ability to interact with the cytoskeleton and for its role in intracellular signaling.

EPHB3 is involved in a wide range of physiological processes in the body. One of its most well-known functions is its role in the development and maintenance of blood vessels. EPHB3 has been shown to play a critical role in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

In addition to its role in blood vessel development, EPHB3 is also involved in the regulation of cell growth, differentiation, and survival. It has been shown to play a role in the regulation of neurogenesis, which is the process by which new neurons are produced, as well as in the regulation of stem cell proliferation.

EPHB3 has also been shown to play a role in the regulation of inflammation and immune response. It has been shown to interact with various immune cells, including T cells and macrophages, and to be involved in the regulation of inflammation.

In addition to its involvement in inflammation and immune response, EPHB3 is also involved in the regulation of pain perception and neurotransmission. It has been shown to play a role in the regulation of pain sensitivity and to be involved in the transmission of pain signals from the brain to the body.

Given its involvement in a wide range of physiological processes, EPHB3 is a potential drug target. Researchers have been interested in developing compounds that can modulate EPHB3 activity in order to treat a variety of diseases, including cancer, neurodegenerative diseases, and pain disorders.

One approach to targeting EPHB3 is to develop small molecules that can modulate its activity. Researchers have used a variety of techniques, including site-directed mutagenesis and cell-based assays, to identify small molecules that can interact with EPHB3 and modulate its activity.

Another approach to targeting EPHB3 is to develop antibodies that can selectively bind to it and inhibit its activity. Researchers have used various techniques, including monoclonal antibodies and complement-dependent integrins, to develop antibodies that can bind to EPHB3 and inhibit its activity.

Once EPHB3 has been targeted by small molecules or antibodies, researchers can test the effectiveness of these treatments by using a variety of techniques. These may include cell-based assays, animal models of the disease, or clinical trials.

In addition to its potential as a drug target, EPHB3 is also a potential biomarker. Its expression has been shown to be affected by a wide range of factors, including disease status, drug treatment, and environmental factors. This makes it a potential source of diagnostic information and a target for researchers to study the underlying mechanisms of various diseases.

Overall, EPHB3 is a complex and highly versatile protein that plays a critical role in a wide range of physiological processes in the body. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate and develop new treatments for a variety of diseases.

Protein Name: EPH Receptor B3

Functions: Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Generally has an overlapping and redundant function with EPHB2. Like EPHB2, functions in axon guidance during development regulating for instance the neurons forming the corpus callosum and the anterior commissure, 2 major interhemispheric connections between the temporal lobes of the cerebral cortex. In addition to its role in axon guidance also plays an important redundant role with other ephrin-B receptors in development and maturation of dendritic spines and the formation of excitatory synapses. Controls other aspects of development through regulation of cell migration and positioning. This includes angiogenesis, palate development and thymic epithelium development for instance. Forward and reverse signaling through the EFNB2/EPHB3 complex also regulate migration and adhesion of cells that tubularize the urethra and septate the cloaca. Finally, plays an important role in intestinal epithelium differentiation segregating progenitor from differentiated cells in the crypt

The "EPHB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPHB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets